Jardiance vs. RVX-208 is quite the apples and oranges comparison. Totally different mechanisms of action, drug targets and minimal overlap in affected clinical endpoints. Jardiance is an SGLT2 inhibitor that blocks glucose resorption from the kidney back into the bloodstream. Basically it lowers blood glucose by making the patient pee more glucose. One of the several metabolic benefits of RVX-208 is to lower blood glucose. This is the only commonality between Jardiance and RVX-208, and the mechanism for glucose lowering by RVX-208 is likely totally different. Plus, glucose and insulin lowering seems to be the only benefit of Jardiance, whereas we all have heard of the myriad of effects of RVX-208. Yes, Jardiance reduces MACE. This only proves that glucose and insulin control have cardiometabolic benefits. RVX-208 affects totally different clinical endpoints (other than a modest glucose lowering), so the mechanism for MACE reduction is different. Jardiance is more of a threat /alternative to other type 2 Diabetes drugs for glucose control /insulin sensitizers and is not for type 1 diabetes. RVX-208 has never been touted for glucose control or insulin sensitivity, but does seem to have modest glucose lowering in some patients and can be used in both types of diabetes. Nowhere in the mechanism of action page for RVX-208 does it list affecting glucose or insulin or SGLT2:

"RVX-208 mediated inhibition affects multiple processes important for CVD. In addition to effects on lipoproteins, RVX-208 represses pathways underlying the pathogenesis of atherosclerosis and acute coronary events, including inflammation, complement, coagulation (thrombosis) and atherogenesis. Based on mechanistic data, we believe that RVX-208 treatment, or select BET inhibition, attenuates the inflammatory process that contributes to disease initiation and progression. Furthermore, we hypothesize that RVX-208 treatment restores basal activity of the inflammatory and innate immune response and clotting cascade with immediate benefits to atherosclerosis and cardiovascular disease. This is consistent with observed reductions in MACE, especially in patients with an acute inflammatory component in CVD."

These two drugs might even compliment one another for MACE reduction. However, we haven't even seen the numbers for RRR of MACE for Jardiance. However, we know in the diabetes population that RVX-208 had a 77% RRR! And this is on top of any diabetes medication they may have been taking at the time!

Best regards,

BDAZ